Magstim announced today that it received FDA 510(k) clearance for its Horizon 3.0 transcranial magnetic stimulation platform.
Horizon 3.0 offers enhanced workflows with navigated transcranial magnetic stimulation (TMS) and analytics for the clinical setting, offering connected care at networked sites, according to a news release.
TMS, a form of non-invasive brain stimulation, uses an electromagnetic coil to stimulate nerve cells in the region of the brain involved in mood control and depression.
Magstim’s Horizon 3.0 platform combines its StimGuide+ to add new layers of quality control analytics and workflow improvements to the first FDA-cleared TMS navigation system designed for the clinical setting, Magstim said.
“We spoke with physicians, patients, researchers and employees and asked them to imagine the next generation of TMS technology,” Magstim CEO Lothar Krinke said in the release. “How can we improve patient care efficacy and efficiencies? Horizon 3.0 is the culmination of Magstim’s foundation in science, technology and our passion to improve patient outcomes.”